[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient of mine complains of over a year of widespread pain all throughout the body, extremely fatigue, anxiety and depression, sleep issues, and diminished cognitive ability. Her tests show that her thyroid health is great; she does not have rheumatoid arthritis, and she is negative for lupus. Her ESR is also normal. She complains of restless leg syndrome and paraesthesia. If she is taking Ibuprofen, which, according to her, is helping a little bit with her pain and does not want to discontinue.  Which of the following will be best for her?\n\nAnswer Choices:\nA. Duloxetine+Gabapentin\nB. Gabapentin\nC. Duloxetine\nD. cyclobenzaprine\nE. Duloxetine+acetamophen\nF. Duloxetine+ cyclobenzaprine"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762206242-nGfHhw6CJVV9Be9YNOni",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"A. Duloxetine + Gabapentin\\n\\nThis picture is most consistent with fibromyalgia (widespread chronic pain, fatigue, sleep disturbance, cognitive complaints, normal inflammatory markers). Duloxetine (an SNRI) is effective for fibromyalgia pain, depression and anxiety; gabapentin (or pregabalin) helps neuropathic symptoms, paresthesias and restless\u2011leg symptoms and can improve sleep. The combination therefore addresses her pain, mood, sleep and paresthesia better than the other options. Ibuprofen can generally be continued if she wishes, but consider nonpharmacologic measures (exercise, sleep hygiene, CBT) and monitor for side effects and interactions.\",\"answer_letter\":\"A\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Considering medication interactions**\n\nDuloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) and is commonly used. Gabapentin, on the other hand, is beneficial for neuropathic symptoms and can aid sleep. I should also mention safety with ibuprofen, and it seems that there are no major interactions reported between these medications. My plan is to produce a concise JSON response that includes an answer text, a short explanation, and a letter designation as \"A\".",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Considering medication interactions**\n\nDuloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) and is commonly used. Gabapentin, on the other hand, is beneficial for neuropathic symptoms and can aid sleep. I should also mention safety with ibuprofen, and it seems that there are no major interactions reported between these medications. My plan is to produce a concise JSON response that includes an answer text, a short explanation, and a letter designation as \"A\".",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSIrEf8FAZsgj8mnyzOYiRJeQpLywnGkFf9WIBjjs1G5LLR6rY08wTUIoaTcXXs1NKygFpmNG-99sfJjX9z-4S6kQvH5JutX3lsfM4zvqsH2NyVroBlX43WrkxtIek7Ro2R4vjVGE8ImMw5nhmHg92fwQHLidXBfv5qRJeI6tdoAQ5eg4XHRY8usrPvbPLvggeY1B-9FaEei4Nr_q3Q7DCHoq39UviFUHd7tFdyB5-oYTt4sSJrYYcagPLp2bCa8jeS5YxfkmN4IzHxPb7KV2Ie5qidYx-FZRC2iqum8X4L2TMbp8NOV2M8KpeRjb9ggDcjbzoDa-OLEIsziKMzqy-bKATowdkHwrBIr1Z1hcEXgeyEXwiM3DHgpL185gCyCQiAXhnJ9aH78X5wtvfNHeAy_u2CyhD2U3cm5IcxZxyb8x1efEiFBn26rVXHq-mXiHLirFbrzPj64BxwsaMMvKogMe3oga1oca4ryLFPbyjmpCw3awyT-2tAVJMZjQ3ZNOBh7HgH5VxHD3u0O_cuDEHz8nIo_7NlTsuXkLJW3g2ENMW1i7KV3gBgdZB-mGn08BF-TWt5iL6W19jEDif2-TwLT23ncweh8qDJl3JVfaeZatJWi0R3KT3DJzDZPrpbXe8UNLKYuhK2sUHWpZmVE_ADLugxWiHg673zMRbJG_dyX0sP4BL7DzYwQwQbhn1ipG2jR7fEq6hncmzRCfH_GY27kxujdMrJK05MuPCbbjyAwVbqSp4uEO07aJoDxThXxj1LZotHbV2216F-dpalp_4mRXhnZX4cC4QqLiK5EWVJIJ7S9N0xgiOYXejMiWLTDWIobEbdyFDTiDiQR1_u_vd7xNOOqjAkync3xJHPXRuKbxDnwXWkdm3scFNNKQs5lqM4kA9vI3EUGFBp59saFBQeQMp15l3cqYnjLz_3IKvcTaOn4DD9yCOGYcz1w_KnpaAEbyTWT7Tx19vUfR4M0-3gwXdzjnHGd74ZdRx9VnkdA4ZrL_bnhHzq0HVHVRDWO03CdDmmb1rynsNnWvZWWrjulpGLMmCcLT5V9OGoBC2hsyAGmYmXSKe_03fkMwtwieA6lH9rtAtts61BjaIXCU2XFFOTTx9lkmUHqcoAwxVHZnO9Ab1KjWXtp-ByhBDEy5mrEFMOfndANTM9OjdLUXLenC1vP44kAQd_KiDzO-d3Q-T5V6Mt7SFsBKuEche8W8RbpLlbiwZj33AIhXTDFBqZTgvLvt8TjiRubo9RYK64h13Y9Ix4GExWNBPSBgT4NW1fTp35ORoVsoGSG-LiO3Br0RpkPrKQCNOSOcKeJvhg_LbdJ_Wy0bmjWpK-1waPopjBiP3XShvhW-_ue_xLlbU6odrUs35fiDkzwd85du3_V_DZL29rEO7SFTHIzlqYJskdg6zhUYfFpyEyALJn_EAlktCg4Wp34ji5txuzfN43PZyeHxEqCaFePHI7yX9P1bPcumKQlwLbf3FWO_xZwmeu183zzbvFenB4eJrvPG2x_SMm199YKXOt23JA09rWHBiZ-uqjdGoWtCIYGcArnob8aI0GzRJyxMfWwk2n830r6VHT1mqF4h9fd9aq1nFDFrW08hb6lLI0j1IlAOdALgl_e9nvUcIKau1AIm0sJdbIWsLEJAoJ3eKOY5_tEVIPwJ1CVzvU6Yjo1xFr088osWrVUarnZlFwOwGybOx9y5UCK20oEhx5nahEsAkJ8xVkuZDC__8cp5kI3pQNmPMePiFdMF7I5t85FdBn6aXIe9GaMKm5X9BvMFal5NlgTu2iL8BTIq8J_QlIznOnlZrDpD5BnIg78qrx4YzhaMo-3C_Su4FSvK6MU3hQX7JABE8OYPe53QZUcPk-v6MUkcpBjcp8tlAbgJXFloXB1HVw871YmLRs-lFJ47j6CPCeK0Qvt70m8C_Vsk-TyVYhMGmFxgWU2VRyXQ2LLwdxrTbbgQ5H0YbHFg8Yah5VK7Ta_cKsnwEjmINCbSVZnsVp0f_5UTS2oVZ-wFsItqFua3fc2BMTHmLt9V4IQYEe_0Fn7e9PIE6019NZ-A4AjYdmXs9vCx0H_gknraLd6iNp4T9pbqK3YgXq1m3DPt94dbjPTwLgr1OjE_q7YE4H6ctcpl2Pr31rQXkHPyRpxEGSrwt0jLCe54J5DH3-G4kFpLKcoYePdgdz7OuM2KgZlq6GsbQsa0zCVZieijzf8FP5EwBj0PUt9Xr77f6s_FaGePY377XQtFiGpXdw6kpkXeqWBT274aAvdYJ4JC3vxHi1hSO6mN2XYOabUAW1VQyVdwC6zBaL6MjeM7BBg4Ab4JCVsEcyYqFXrsHv-KRBwg6yyH_y8dC7d1Wjzo5esQhj-GsCfm4-eDtXVQkVaN9agBABdksgyTz2EZCFCPLoouXGee0HL5QMwbbgvbxqOYm76wQJmbdz9NBr0h1tYryL7aItH0ccFFetRxHIGgIuOL7Me73ks1ghZOtuutVa5MJG8blLXWWEMDjyKWgSILKbWHT34D1nEO93U8ABsWmT3PWapu1ZeAWZWT7HmbEFkQ0VqkU2HIG2BZXNlTv4fvZ8CYSQ7Ia6buXMwlLtF3O34x2QojiBSkEkEjajCL2rJ04QVW4zk2LIg3jGDdLfUbc85t2sQLzumyf1BKPeRiNwCXv4Qbqxm_nc5pV0=",
                "id": "rs_0d2e85352faa86d2016909222407cc8194b5e7786683cf8b3b",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762206242,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 410,
        "prompt_tokens": 210,
        "total_tokens": 620,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 256,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0008725,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 5.25e-05,
          "upstream_inference_completions_cost": 0.00082
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient of mine complains of over a year of widespread pain all throughout the body, extremely fatigue, anxiety and depression, sleep issues, and diminished cognitive ability. Her tests show that her thyroid health is great; she does not have rheumatoid arthritis, and she is negative for lupus. Her ESR is also normal. She complains of restless leg syndrome and paraesthesia. If she is taking Ibuprofen, which, according to her, is helping a little bit with her pain and does not want to discontinue.  Which of the following will be best for her?\n\nAnswer Choices:\nA. Duloxetine+Gabapentin\nB. Gabapentin\nC. Duloxetine\nD. cyclobenzaprine\nE. Duloxetine+acetamophen\nF. Duloxetine+ cyclobenzaprine"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762206242-hcs7BXwO7fYIqaUzLuxr",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"A. Duloxetine + Gabapentin\\n\\nThis presentation is most consistent with fibromyalgia (widespread chronic pain, fatigue, sleep disturbance, cognitive complaints, normal inflammatory/autoimmune testing, plus paresthesia/restless legs). Duloxetine (SNRI) is evidence-based for fibromyalgia and treats pain, depression, and fatigue. Gabapentin (or pregabalin) targets neuropathic symptoms, improves sleep and restless\u2011leg/paresthesia symptoms, and can be additive to an SNRI. Start duloxetine low (e.g. 30 mg then 60 mg daily) and titrate gabapentin (risk of sedation/dizziness) as tolerated. Also recommend nonpharmacologic therapies (exercise, CBT, sleep hygiene). Monitor for sedation and any serotonergic interactions.\",\"answer_letter\":\"A\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": null,
            "reasoning_details": [
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSIqjRlGkAEt14rU2yUx8nRPZ7rd30sKkDRdAjqRu52Jg7vYQHfUDT74E009g1I9gP_Cj_WmNxTqt7miobrjljAV7-A_vx61HRUTKfj5mFUNytVd_cq51KNM8wrpqMvj8nfzoS5LPIa1p3Op84efFQK0TLIJNsLboGF7MwPGwfgo0lGTcHygBeutyX3Z9Y8NXiawLA3UjLMnN05YQn6RlH0AayB2k2V8lGemgKXztGSUY2WVpn9qF759dvgXqkEOtjYAv9reVNuoASGxNiBpA7IdpxvDeIR_QGB3CCiTa-ADKKlJNNDcCLj3GQsemHxMxoYM07LI28C3BoFZfg8_6BNPSQwImpoUd0w4GwJY8mku8kAQkO8p5tTsRnPHkabsAqtadzjrAHwvyJnpIfSrBgYPlsIvW-Q7sWPfkHSe-I2xwF4AfguXW0n5DjHMjG6iIbGFNvia1P_eX_U7MvbXns1aE6PCLWewHTLkwtTRKzsO_az9M1zRhdd2mRfxFsl0-basygtDYOfEDfbVnwgm9Pa_JMNoe_1D10ikWYG-Zv_1ynSy6ER7zWffHtlNo8xgbz5LxoUUw9hpxB_Z5ahKUA1aRQ9i-KpQheIoftYqYvzoUAwhO_oh2mQRUmAvpM-xzTC9zYVjss4PB57Zn_H4IvGS1_aS2OPTPwqS2WUTl4fl-wtc0txAmcgTX7QNo7zoyd1t4WOOgRXj2lZy5yE9MYr0BDvOVNIGd5osf30lnB9CN-jsoqWSFv-on1-Z2w1sDaikXOkOCC3TehFO_g-fEl1wDaxbWUM9LK8K6f0_DmUku2GXgz1Xu2HbHTVsqoBYgADq8zslkuMHtgMg73LnC0jKl0WsMWs9NuqhNlpEta9I8KInPJWWR208-fPJBDzrI4j4czuOvnTs_zTkT-ZgD-Vs-wsKaPRMMNFD101RHHyyJLDNIeA-UmIpqkPZiW1VS3TM8UEVyrbMUh8LlnxxDqbwVSITIFfo9iHnO4GTLQIotaoU5gjlc42HDsm-mF4EfvyYJA0bNM8Ro-ZouxGsbWkRW2hVB-I3gQ7NedKez74wvBLOcgx2WsdK6rnEhu9AWPhCeYcUXvwuJnKpP8TDiN9EJvRnMvzO7oOi8hF589twm6X8ZbS0yeb0wQjkrIDtwZiYhTK4ilWxKU0kQqC7qe6S0cQH6nkv9BNbCxY_GxVk8iGOWuxK3flsvK9hAGqxe2MswcSFXu91vqc9-OkI0jyIgszh66Ez_xlD6FrjuCW1eAureqpLwDcbMzO-G91MjFnOtr-kOHVulHglg8NkV46NGxenKlct017eEH-SOokXiFwPiCjly1xvl6PrBJ8rS3c81DN4QQ2AB_Hv-6lOQZLA7fJ9hUyLgpnDvRhTXiczH-O6VOOqT_TnBU5lGDNjiZBJl9TTN6l2eG4UUsDvgJp_Cu3oUS2_YXZbaI0XEolTexsesF_rAO1oqPpiOVhXq8g0O3rd2HbAwpMa4GeOMNNgKY38Vqcm9S6gAHpKzK_oMF8Tj5qaXS6sJg4mWgrHyEgBATb9phmUmw9Qgqvr1nDwNsrzRPCiJTCCHryXmvauqjHq5_Krsknbi4kCwOLP6ffiiyIglKxPxDltS4GUYXwpnRo3gSj4Klk3UhWrtaYO2kntTt3zwUkaIozjWtVZTysifvTvcGIfMZD4fbKrt4cWnAB2H87XxDLlJlqUaW1HHjn2oloUYF5aYBAu8VsM6tdXVg4i2jfEmhPi5no52W3A2VnaKVg1JX3V4cijhIErmAXlhxC0t5JyZb5RVq69J_-cR9S3ZVmzKptckK0oc-SI9xBeECvcPeZBgGmbFT1P6N27NoMzd0Ua86RZpzkP5dmaSiMeCp1JjyNWbLZS8fa7FZ3bZVk5Es1t5ZtIgcLUL7dctgFkZ5xnPszYqc-Fce_ZuWFtBJMjwjk5l9FvadtRJwKZkX2uWkvqCyqdtn5WcgpU2SHhLodKrXWi6wsNFtyJ5rdTnj8hFvlR8zl-X3ndMQtCUTQ1KyT_o54Fp4qQOyHs_RQUif5My5wrj0IaPnPBgGYZAeUi4_yfD0jDHyaWOqgS5FTMa4I1fkkmVVhZ6EbKdA96LOC1_U1cTVdQzQnkwhsOV5tNmyCkqY02LRMerqQ3Q2zCTzEf0hi-uKirH879VObbrD4eBYXX8nt51YTKpx3fmQGQOPUZdY-yibzCmXyNfT2uvPUJ1Nsd9m2dXWy-KzfSJ7uw8I9pvrvdcap4ezQMvCuK__qe9VFk7Mc-xW8avsg2ecur2YBHgj9LNzDokNm3J3ZAtv-HhWauMb2gGBpG-N-mDIczuD1HwVKhLR_ytQsh0GlHY8lQl9nOzpQ4E8LWuiPj3ifcVKPchqiFllYNeEdAIyl0tXPakctXkYc8q2qZaZOYoT7BU7u22HeTnx28xBAtmklpvxONsBXx8pokBefUxNKi52_NUaHkjbwEct1M7qvnTDzXk_pWCVeZ4-K63bytEQf9FyoxEcWV5Du6r3KK9WmacGuvc_ACV6WcO-eMl1ANBlDYIVPYzQ7tWDiEg--IxHDHk24W0RQ_Zdqab5vv0zifGU7wKmseA-mH9XmWpj_8irdeZVeeQuA9XJRLbg6OnBHOti8o4W6zjpUdohLCuM3wHvDgPh1Nxzp4eKqu_WXAi6RsitAcqwWj0y-fikFG6rjz_7yRykFdacWMc-QYqMu4GGrHCzDwvekinM9n_sAbYqpskJ9LeAdKLpCPSO-iIGk6f4S7LcXmPnV9e5HfMZ0FKwzTRewWGiSYU1XMeJQImfask9rPVSeTaCvkWJZtOri5Fxn8qTyo5wkHUuvBqobUaOiVgMhmsotMfW34jytFlinHsOkbSkH7VBU7TppWAM-k3mN642z-PsfF0k2RKy1OOU0jf3hOH7Qzcb_oU0VTUruGpKK9hioIyU_yDrNxZaokBcWqYNrhlLPQjv0Ezbpt5MPBatSrFOcrSFGUWFoKfpgC2-CLtleYQeofnCUah9UZnEclP1-RjQrohhFA7Zq02pgI6zVwTj5jIktVTiQeB2bZ_Emec2gayCSbFUDuG31QO0HfstC6HheaDq8yYE74zLVRNlcgRciSY6lK2XyI12UH4HrG3Y7GnDmfku9N4tNFot5JMPiBhsxXx047VW6zcXXnQeFtqjfCNFDF4CAu46BfzDmhYqhtbfspSdcuM3XV2fUD7GEXLVfRaDvrNxoEawZQRXBOQFZnRIoGWJRTXCqpbHHjipdnVO5gW12hjEke014zq2XuCRF4FPdm380ZKhr4Q2mY4Bw_MQyUY3XtSgvoxyBH8xa9HxxxTyRMJ7J1i68MxOHYrjvIut6LZnVbohJqu4SsdtFx2q7iSvag4hUbno1p0OnUeKiaQ2KgiQ302bkwFnTGr-tujICGjUQ2w6GF8v6b-InoOG4jBurNT4QTtIVFbU1eY2vM8kdssj6KBdZspVphXZooT5nBTrbeZj_fJYoqAb-JVmb2BGtUjonyiQ-s8VlAR_yXOFVVpFuE0HEn4gTGyEHBHpKTXfiNQy7ZfZylDNTakWcC8DIEA7wW3SZkyCNr6agGr4UKwa4XsytxEAo3boTeSLFO4ugTy5vNvZwlZODu7GpI8BJ1rUBy6lrSUSMLUFC5U21G4INtd7bWgpsghHDcJQt5zF-PSOw55qvsNDYaL_ax8Omatk3Xpdi8S-27ABOvzWKUfQcnISWfHpqm5CVD5GwkMfejeWO5vNwkKfvGBwEN1kUSuptuvZvuzwUfZpMT7l0mYPYYOjpzrjwRc0QTltVYYgokUcxTgmMXQ3mf0nDDUEr1cK8IgYxKNZJi0gqFICQxA2QHNEbjli4yufM5Umk1s580QyYLQ99Wu5zGddxbO6R3iDUFhDDtqwXkdkS_uLdYQjeGFHu2ZU2hGcftltRpMPId7SStC2DGRc1tBemQ8DrGzGVSpB4v7SoFJBdyvQ6x7JTcqxcGdo-l9wPAqOx7Ci5OdrkO9k2DWtNBBN_qiSrugJKXUQL3j66Oh8shhoP_vN_4a4onX_NSSfr_gp__sKOkBN9kbZ9PC9wWOtsBFZqkZ4tPQpBy_rk=",
                "id": "rs_0c5e718f6b59168c01690922239bb081978be7f75dad6ed3db",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762206242,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 691,
        "prompt_tokens": 210,
        "total_tokens": 901,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 512,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0014345,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 5.25e-05,
          "upstream_inference_completions_cost": 0.001382
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient of mine complains of over a year of widespread pain all throughout the body, extremely fatigue, anxiety and depression, sleep issues, and diminished cognitive ability. Her tests show that her thyroid health is great; she does not have rheumatoid arthritis, and she is negative for lupus. Her ESR is also normal. She complains of restless leg syndrome and paraesthesia. If she is taking Ibuprofen, which, according to her, is helping a little bit with her pain and does not want to discontinue.  Which of the following will be best for her?\n\nAnswer Choices:\nA. Duloxetine+Gabapentin\nB. Gabapentin\nC. Duloxetine\nD. cyclobenzaprine\nE. Duloxetine+acetamophen\nF. Duloxetine+ cyclobenzaprine"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762206242-c0UDTCoN95JDkgKAw1kf",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"A. Duloxetine + Gabapentin\\n\\nThis clinical picture is most consistent with fibromyalgia (widespread pain, fatigue, sleep disturbance, cognitive complaints, normal inflammatory testing, plus paresthesia/restless legs). Duloxetine (an SNRI) addresses pain and comorbid depression/anxiety; gabapentin (or pregabalin) treats neuropathic symptoms, sleep disturbance and restless\u2011legs\u2013type symptoms. The combination is commonly used when single agents are insufficient. \\n\\nPractical points: start low and titrate, counsel about dizziness/sedation and possible weight changes, monitor mood/suicidality as appropriate, and continue non\u2011pharmacologic measures (graded exercise, CBT, sleep hygiene). Cyclobenzaprine can help nocturnal pain/insomnia but won\u2019t treat mood/neuropathic features as well; acetaminophen/ibuprofen may be continued for adjunctive relief.\",\"answer_letter\":\"A\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Analyzing treatment options**\n\nIt seems like I need to choose the best treatment option based on a likely exam question. The top choice appears to be duloxetine combined with gabapentin because it addresses both mood and neuropathic pain and helps with restless legs and sleep. Ibuprofen can continue as well. I plan to craft a clear answer highlighting the effectiveness of these medications for treating fibromyalgia and suggest non-pharmacologic treatments, all while keeping it concise.**Cautioning about medication interactions**\n\nI need to provide a brief explanation concerning the risk of serotonin syndrome when combining SNRIs with other serotonergic agents. It\u2019s important to note that gabapentin isn\u2019t serotonergic, so it\u2019s safe in this case. I\u2019ll also mention the need to monitor for sedation, dizziness, and suicidal ideation, especially in young adults. Furthermore, I should include a warning about pregabalin as an alternative while suggesting it if needed. Time to finalize this information!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Analyzing treatment options**\n\nIt seems like I need to choose the best treatment option based on a likely exam question. The top choice appears to be duloxetine combined with gabapentin because it addresses both mood and neuropathic pain and helps with restless legs and sleep. Ibuprofen can continue as well. I plan to craft a clear answer highlighting the effectiveness of these medications for treating fibromyalgia and suggest non-pharmacologic treatments, all while keeping it concise.**Cautioning about medication interactions**\n\nI need to provide a brief explanation concerning the risk of serotonin syndrome when combining SNRIs with other serotonergic agents. It\u2019s important to note that gabapentin isn\u2019t serotonergic, so it\u2019s safe in this case. I\u2019ll also mention the need to monitor for sedation, dizziness, and suicidal ideation, especially in young adults. Furthermore, I should include a warning about pregabalin as an alternative while suggesting it if needed. Time to finalize this information!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSIyInJNHouODiwcAPrdh1rzG-BevWUlMP8t8jlVu3-2pSKcmRmNpl5aIerrElT6tuVU6Gzl-3RRZXt3KmzF7vRSZ9D3dSU5xgtzBvCzmydKNjL1lFJyj3lS2ueWs9ISs02pniGaZJsSy1r7_NdjHjRt0b8yBTEQ8b4jDpmPRmYR00tewSCP6Cenx8xlayU-c_hb2ET-jQjB_ltnCbcQrmsf-VWm3SPFJeeQ9k-UqoTavlVtET-n8nZ_YlAE3fj-hv06bNK_Rh3y-4sxehd9yO_0ESrsTvXJKwMx7ZgHb6eYHlObzdbnNVfSBP7n9edlnJ0m3E3jXTKtsAml2uJKuyeq9ejjDarlOC8VCnkLAnDxnKySNgAoe1vH1ObCTGjQyrqcsbH6DeUH5BYRWQitAgaikqRMMs20RsQvXlIMW8nvZBRWrp0OpAa-TAW7r82FZpJ3GGk4NdWiDDbwUZh3d2J8c86PzZ0ahsko8WdA0ok2EL8kooJs6mzqpxScsI1wrqYsz1hHp_78rDUfdwkN85dynW6kTLEsitst86jjBnh1nMDIn2q-21nYhL0vk787668jCo1QMWTJVLhbjf_JjbQFb_45do_Euuh3S3W6fni_Wh7mi7f7o9LkCLSUxoqAOn4_Noo_-TT31LzhElFyt5qFdj-raVHvANMqHbWA-nRM549gL363rLBHzz6hlaAbXQJsG4_NzPQEkoMm7jrl3ZGEi0ENcF40cBM9RmSzfHTQqFngIOfYxoi9CX5ta-an9eGDKNzOomdcT2MvVU5m7Bfp-in5ElBjm7h_mxv2Gxrw59hMe-wghaKm0qzmCiPCau9kWpcpsn_omknJG3T8jjdjQgzhd9HbX2RoKdRVxpZUy_3nwVO51POSx9MBb_zQDmIat1xtio3GCVyB5ZD9g2eBReODLnTp2dXkQ060BFesBhG7eUTL5nVekFmc5lnYAMMpzTXX5vO9iX_7M_O_s7vfiX_uZY-j8Pal19_f1BcV9IsP49PLPasFEZtEjA77R5zVm7zL69ORsgKPupBCtUbi0gMFLnGp5EglEi4quYj5V8RlXBIYnzHrMfMHwsNJelHhQaLaBuQV7kIK7FpGwB7MvO9k34STjnuHaWbsy15lm7JrATBsU51AnLwKs1FnL0PYFE5vd9OpiZc-TD4sQDtA3_8wU6rY7-S6Eth5Lg9t25RJLcW4XFjhgcNgYqdgczZIXw9sfrzuPB0_4PZijXMH_9YnQsba8iOwvXGpBKFKdJ8t9uGQlJrIwUoj3x4891R3bdKW0ln6yGit0rjZm75oJJuFp89N9mMnHoFfpxBXL6QeB57nhC3im9Rq7HAE5hEZYXr3MF45Ox6xZgxvknMenrW4PBY7pOUG57lRB7M9vuEE0dW8V73wFsXxpU2dhI2s5Lbk59AwYChXHK85-eDCHB-7INWnIyOiMc3wDtJKgY2coI9J4DdMC-DpmX6CSaomQBdCqj1eYuiMrnW-w3YROca2iNKLVjlRzTjD4GfEvzyjeY3w3site-fn3yUepJxDXdNdftwnfSt1ERQ-k2LyGODNf12pGkrmOjYPGI6GlYv3XmbgJgtKigJrV6SXNEjIV5KYsM-YRkS6F229RkLTjEEfdL-nZ633ImZtP1OEF2UzDR4YXSAQagO89lIOxaZ63gMTxN2AV6g2XIAe9ofZghddKfQ9mcArkS5v6L1NdWtDA3ZEgBg3rY2G6I_f5al0rexUSrRW8afN0R9wE0RF8XvCsQVgINgyCzi6VximGR24hW1cdy9g03Js03yuj7P68kESAI0kIMHsKBjQkqk3H3ulBw4BNg4y-m6jypfjRlCMU69lkSDBjlirI22IMKdSCA5Z38XJrj0Fmw1fDSmIyez0x7be3ozRGgPvNSj19xnQFbEDroKv7VqmT-EEjHmy4JVGojt2ivb_pxXM_zGJMKfIfCDoSRN3UnKi9NIkOaO45OOWA5HRVhCx3C7bDH7nqb1gRwBN8BNzxxAxUSaDXGFyCeiUL8ed3Xc43WuOM5CLbU9i2QethZM8gMNdDDy__dxLnHs4INFokDXLWgULAFgyDtsYDgLnnIzOULn_VgVHsqCVfh-0rK_ILdj1vA2K7jlS30p1x6J9oN-Np0uVRh4w38PBN0EptfBnDwJsqH0mhfkiIgTdEEnxi2DeumMBZpw60e9sOx380Ow6KCu1X31YGfKTi5oLLaocI4hXj6VXUXi46599PZ-qf0yGlia5mcBz0VIyoi62Daal3kOMAZWt4zJB06uDSRhaXATLD2QsKAiwhkQgFM6srvQ1juutM3twt6aqrR6oDKLLlael26zlmlW6n98ZJv_3jphkcsfqD6hbXvN3fex0AOJM5bBhJAGC32OMT-b9zHBpFrDhPd1mPDfeOq9M9gpx1Rh6_8NdnSVpQTVsTSwr2qXNBVW0gC1NH5NyyDN3CRrArlCljnyxLWNpD0HFl9QgUFnq64t_GJNocrJ1ld1o6yrc-4nBITyMqPSAfcra54pwyCb8x63hzAAqomkIOAhAr5QrAbyBmbDHeJvPAch-nVJydw-OK-1486RrhamfQRXZwQ13E-8lqmHyBneNVq9YF6po2l-XSF-hmO6gU7CUtj93aAqQwJBe-M4vJ1nECS1EVY5zJchG1lSdFbTEO8eRpeD-6tCaZFWvi0Scoz7_eW8vuDuIF-cVCEGbUVZgCQ0Cg8aY3kVnGBrhFKEFHxh2xsIIS6GQrZFets-vpKM8knuIde6zu8JenV6qHA6tmv44JZhwrvnjod0cTvyOc9xDGuQO4uf3Pi2AZ4AsxFsGnSYCpxXc5RbylF9QttDNDrUkSF6Jhf8EojIOef-4GMzzoqMR-rFZcQb_QffkIJJZhHHQYLKTFhFIeIkHcVa6n-RYpDmX6orS8sQyOUvwEx9cg3U3ipfc9BmfKgeuQOQpZzGQg1hSfEdHgCQc4YuAHN8naAO_rgtnyvedAAXYSjP-4m-wis1B_W6louY7vGekjCZq9bKtLfg4aZF55D3Hx1l3zNHSqrc1bUMgUHqpmqhU8a058rNCeXwpcG1bscy6YH_2Lxa46Gt8wjYpI67hPpi86ekDiC0qHc-RSJEZD_X3SPoRbdApHuQncyrld6RhOr2YvehvH3VLc3_KTFMukxWaW9XHeQjAO9g20V6iDo3D63FRgni_SiBjjNGas9wh5txi2kHv7L3M6BTRnVkGP9BT5Y6o-ARab1sJP8H7E_WUysy6eNpGuzNZv9DdW0YBzZPsNFi0VS26WasCzVB7y5S5waMV0oC5y73dmr2w0lSdqRKzyrSMdUoVKwCGJaNRrasxm2u27sLMk-zdD-0_MsGsEY8kWTJIoa765kECAMvCRLPNmR6Cet7I6znKVdOPr1uJ9U7NXIr2tSkUjJZvx-pphAKhs9AkHILjXDz-xtWZG6OE462wHx7D1sTuC9bdFuN5Hdmqis6tYRyPOdV4I6xZ7tFhx_ISYsh0jj_j34mKbMv8u8cQHOxBMvhUE1ZWM1RcPfJRWyaQvnPrErG2OrlbqBG8yJqGQGYMi-zQoagROqPJ_beSAdw1DFX_lIAoLJfeZv-YBQ1IM_DO_H_Z5hAejjz2nVKFonoFQy1fuaVDy9KJI5y9EMkidBtC5lS5wn73bw0KV8I-jTeHG08zITmfA4GV6HPMQImLKELq-RZtDvBaC1JieK7rOyQqkzwY47CHZT8IrozFbBj0_Ni4TTsfcaDXzrZnancyEnoJr3m0ZmuwFqNJ9N3K7Y-0ffB0pJ1GNrwILxnIrxG4FU54THiUeEMRNHs6VjB_3MTSWv9UQZIUVZf_lNilAwhrQBh8pUViI7dbOC3djtEJUhpIeA3a6XBEalj57TjxhOvK4X-RcB07F54c6Hk21A_QG9r3DTyv5zQrRPQS9pg-PQVjRleQdQs_Nfrbi2b9qomATl2yIY1Gv_DPejtkH3j4xuyFf90SECJN3OhoJ44QFKqfGfRkVAshEg7T_a7NB8OvbwvKUajUru89F0XTUX-UNqVL5NXz3Krpe0cNOC--Ve4HIEx7_t_OWA==",
                "id": "rs_0145bf26a3be08c50169092223a9308194a5f88acdc0b28f29",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762206242,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 719,
        "prompt_tokens": 210,
        "total_tokens": 929,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 512,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.0014905,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 5.25e-05,
          "upstream_inference_completions_cost": 0.001438
        }
      },
      "provider": "OpenAI"
    }
  }
]